Principal Investigator (PI)
The Foundation is providing £195,071 in support.
Katrien Sutherland
The aim to link in with the scientific and technical expertise at GSK through assay development, specifically for the compound screening and the PK/PD component for which we have no in house expertise. We are an applied bacteriology laboratory with limited exposure to medicinal chemistry and drug development; therefore, this is an ideal collaboration to combine different skillsets and apply them to investigating new approaches for drug development. Additionally, by accessing expertise in formulation and animal models it will aid in refining the drug combinations that can/or cannot be developed.
This is important study in the field of AMR in Gram negative organisms and moves things forward to study the potential utility of combination therapy for treating bacterial infections. We have shown synergy with tebipenem against other invasive Salmonella, and we aim to expand this scope to other drugs against an important set of pathogens in Africa. This has not been performed before and may lead into the identification of antimicrobial combinations that can be trialled to treat iNTS in Africa. Additionally, the use of organoids and a more physiological animal model for these human adapted almonella may be a more appropriate approach for identifying new antimicrobials.